• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

0.1 to 0.5 Percent of SARS-CoV-2 Infections Become Persistent

Medically reviewed by Carmen Pope, BPharm. Last updated on March 1, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, March 1, 2024 -- About 0.1 to 0.5 percent of severe acute respiratory syndrome coronavirus 2 (SAS-CoV-2) infections become persistent, lasting for at least 60 days, according to a study published online Feb. 21 in Nature.

Mahan Ghafari, Ph.D., from the University of Oxford in the United Kingdom, and colleagues examined the population prevalence of persistent SARS-CoV-2 infections, their viral load kinetics, and evolutionary dynamics over the course of infections. Overall, 381 individuals with SARS-CoV-2 RNA at high-titer persisting for at least 30 days were identified; of these individuals, 54 had viral RNA persisting for at least 60 days ("persistent infections").

The researchers found that the odds of self-reporting long COVID were more than 50 percent higher for individuals with persistent infection compared with those with nonpersistent infection. An estimated 0.1 to 0.5 percent of infections may become persistent, lasting for at least 60 days, and with typically rebounding high viral loads. Many viral amino acid substitutions were identified in some patients, indicating periods of strong positive selection, while others had no consensus change in the sequences for prolonged periods, indicating weak selection. These substitutions included lineage-defining mutations for SARS-CoV-2 variants and at target sites for monoclonal antibodies; they were also commonly found in immunocompromised individuals.

"Our observations highlight the continuing importance of community-based genomic surveillance both to monitor the emergence and spread of new variants and to gain a fundamental understanding of the natural history and evolution of novel pathogens and their clinical implications for patients," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted March 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.